Mergers and acquisitions
In 2005, Siemens Medical Solutions USA, Inc. acquired CTI Molecular Imaging for $1 billion (€750 million, $20.50 per share) incorporating it into its Advanced Imaging business.[56]
In 2006, the business announced it would acquire Diagnostics Products Corporation for around $1.9 billion (€1.5 billion). Established in 1971, Diagnostics Products Corporation produced immunodiagnostics and supplies for fertility diagnosis and in-vitro allergy testing, with the business being incorporated into the Laboratory Diagnostics division post-deal.[57] In the same year the company announced it would acquire Bayer's Diagnostics division, for €4.2 billion, boosting the business's offerings in a range of services for in-vitro diagnosis.[58]
In November 2007, Siemens announced it would further expand its laboratory diagnostics range, via the acquisition of Dade Behring, producer of clinical laboratory equipment and products for routine chemistry testing, immunodiagnostics (including infectious disease testing), hemostasis testing, and microbiology.[59]
In November 2011 the business acquired MobileMD,[60] later divesting the business in 2014 to Cerner for $1.3 billion (€970 million).[61]
In September 2012 the company announced it would acquire Penrith Corporation, manufacturer of ultrasound imaging systems.[62]
In November 2016, Siemens Healthineers (via Siemens Healthcare GmbH) acquired Conworx Technology GmbH, a Berlin-based developer of point-of-care device interfaces and data management solutions.[63]
In May 2016, Siemens Healthineers expanded its molecular diagnostics portfolio with the acquisition of NEO New Oncology AG.[64]
In April 2017, Siemens Healthineers expanded into radiological information systems with the acquisition of Medicalis Corporation.[65]
In 2019, the business announced the acquisition of vascular robotics start-up, Corindus, for $1.1 billion (€980 million).[66]
In August 2020, the business announced it would acquire Varian Medical Systems, for $16.4 billion (€13.9 billion), representing a return to radiation therapy after the discontinuation of Siemens' own linear accelerators in 2011.[67][68] After the merger Varian will continue to operate as an independent company and will retain its headquarters along with its 10,000 employees.[69][70]
In August 2024, Siemens Healthineers bought the diagnostic arm of Advanced Accelerator Applications that specialises in producing radioactive chemicals used for cancer scan for more than $224 million.[71]
